Agenda 2020 

Day 1- Wednesday 23rd September 2020

round tables
13:00

Roundtables

Public policy and the patient voice in defining market access solutions
Sue O'Leary

Sue O'Leary, Vice President, Global Market Access, Prime Global

Roundtable 3: A tale of two diseases: how orphan drugs can navigate NICE
Josie Godfrey

Josie Godfrey, Director, JG Zebra Consulting

Roundtable 4: Achieving greater appeal for Value Based Agreements
Hassan Bruneo

Hassan Bruneo, Associate Director, Alnylam Switzerland Gmbh

Roundtable 5: Using Health Economic Studies to Support Access and Value
Fabrizio Gianfrate

Fabrizio Gianfrate, Professor Of Health Economics, Market Access Advisor, Universities of Rome and Ferrara

Roundtable 6: Accelerating access to treatments for rare diseases
Kate Adcock

Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.

Roundtable 7: Does pricing innovative drugs fairly improve your bottomline?
Michael Schroter

Michael Schroter, Partner, Viopas Partners

VALUE: Delivery & Perspective

BIG DATA, DIGITAL & ANALYTICS: Innovation in Access & Pricing

MANAGED ACCESS ENTRY AGREEMENTS: Implementation & Considerations

AFFORDABILITY: Political Factors & Health Outcomes

14:20

Exploring value-added medicines

Maja Sercic, Policy & Science Manager, Medicines for Europe
14:20

Exploring the use of Managed Entry Agreements in the Middle East

Camille Harfouche, Rare Diseases and Access Lead, Algorithm
14:50

Live Q/A Panel Discussion

14:50

Live Q/A Panel Discussion

14:50

Live Q/A Panel Discussion

14:50

Live Q/A Panel Discussion

round tables
15:05

Roundtables

Roundtable 1: Efficacy to Effectiveness - E2E – translating the promise of clinical trials to the real world
Chris Pashos

Chris Pashos, Former Vice President Of Global Evidence Strategy, AbbVie

Roundtable 2: Access and HTA considerations for Turkey and Ukraine
Oresta Piniazhko

Oresta Piniazhko, Director, Hta Department, Ministry of Health of Ukraine

Roundtable 3: Exploring the value from repurposing drugs: Who Benefits?
Douglas Foerster

Douglas Foerster, Head Market Access, Santhera Pharmaceuticals

Roundtable 4: Exploring challenges and opportunities across Africa on achieving new affordable strategies for Universal Health Coverage
Sagie Pillay

Sagie Pillay, Chief Operating Officer, Wits Health Consortium

Roundtable 5: Exploring innovative reimbursement and payment models for orphan drugs
Jaime Espin

Jaime Espin, Professor, Andalusian School Of Public Health

Roundtable 6: Market Access and pricing considerations for Spain
Carme Pinyol

Carme Pinyol, Head Of Pricing And Market Access Southern Europe, Pierre Fabre

Roundtable 7: How do you include the patient perspective in a outcomes-based contract?
Girisha Fernando

Girisha Fernando, CEO, Lyfegen HealthTech AG

Roundtable 8: Perspectives on remote project delivery for global pricing and market access functions: operational aspects and life hacks that ensure market access continuity
James Wright

James Wright, Director, Valid Insight

VALUE: Delivery & Perspective

BIG DATA, DIGITAL & DIAGNOSTICS: Innovation in Access, Pricing, Diagnostics & RWD

MANAGED ENTRY AGREEEMENTS: Patient & Payer Perspectives

BIOSIMILARS & VALUE ADDED MEDICINES: Considerations & Legislation

16:00

Chair’s remarks

Meindert Boysen, Director of the Centre for Health Technology Evaluation, National Institute for Health and Care Excellence
16:05

What does value mean for LMIC countries?

Rabia Kahveci, Senior Technical Advisor on Pharmaceutical Policies and Governance, Management Sciences for Health
16:50

Live Q/A Panel Discussion

16:50

Live Q/A Panel Discussion

16:50

Live Q/A Panel Discussion

16:50

Live Q/A Panel Discussion

GOVERNMENTAL AFFAIRS: The Role of Government

BIG DATA, DIGITAL & ANALYTICS: Digital Medicines & Pricing

PATIENT ADVOCACY: The Value of Advocacy

CONTRACTING, PRICE TENDERING & PAYER COMMUNICATION: Innovation in Contracting & Payer Communications

17:05

Chair’s remarks

Chris Wasden, Head of HappifyDTx, Happify Health
17:25

How to build and communicate a convincing customer value proposition in tendering

Nico Bacharidis, Former Global Tender Lead And Founder Of Growpal, Pfizer
17:40

Insight into US Government Policy and Payer strategy

Erin Mistry, SVP, Head of Payer Strategy, Gov’t Affairs and Trade Relations, CorMedix Inc
17:40

Using a digital pricing and market access simulator App to enhance product development

Raf De Wilde, Senior Executive Advisor, Valid Insight
17:40

Multi-, Cross-, Omni-Channel Evolution in Payer Communications

Stephanie Chen, Associate Director, Global Access Marketing Oncology, Bayer
17:55

Live Q/A Panel Discussion

17:55

Live Q/A Panel Discussion

17:55

Live Q/A Panel Discussion

17:55

Live Q/A Panel Discussion

Chair’s Closing Remarks

Chair’s Closing Remarks

Chair’s Closing Remarks

Chair’s Closing Remarks

last published: 19/Sep/20 18:55 GMT

Day 2- Thursday 24th September 2020

Morning Plenary

Erik Van Den Berg
10:00

Innovation in industry and practical considerations for biotechs

Ion Agirrezabal
10:20

Trends in modelling approaches for successful reimbursement of ATMPs

Dr Bharat Tewarie
10:40

Interview: Unleash the Algorithms: Critical Success Factors to Reinvent Our Role in Delivering Patient Value

Isabell Remus
11:20

Embracing competition to deliver the true value of biosimilars

Isabell Remus, Head Biopharmaceuticals Europe, Sandoz
11:40

Live Q/A Panel Discussion

round tables
12:00

Roundtables

Roundtable 10: Branded combo-pricing: Where too next?
Yves Samel

Yves Samel, Market Access Strategy Leader And Global Pricing Manager, Bayer

Roundtable 11: New HTA requirements in France: impact of unmet need on access
Bruno DE PAZ

Bruno DE PAZ, Chief Executive Officer, Prioritis Market Access

Roundtable 1: Open
Roundtable 2: Pricing Strategy – What to Do and When?
Andreia Ribeiro

Andreia Ribeiro, Director, Lifescience Dynamics Ltd

Roundtable 3: Exploring reimbursement models: Working with external stakeholders to improve outcomes
Gomathi Kaliappan

Gomathi Kaliappan, Global Market Access - Health Systems Strategy, Value Recognition, Roche

Roundtable 4: Challenges associated with communicating the value of Cell & Gene Therapies
Roundtable 6: What if you could listen to 1,000,000,000 authentic patient voices? Turning real-world conversations into evidence
Yannick Loonus

Yannick Loonus, Chief Sales Officer, Semalytix GmbH

Roundtable 8: Achieving greater collaboration amongst payers, HTAs, pharma and patients to improve outcomes
Jost Leemhuis

Jost Leemhuis, Head Of Safety Science, Roche

Roundtable 9: Advanced Therapies: The role of registries in convincing payers about long-term effects
Alexander Natz

Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)

Afternoon Plenary

Thomas Mueller
12:50

Interview: Orphan Drugs, Gene Therapies, Post-Marketing-Data: Latest developments in German legal framework for drug assessment and reimbursement

David Thompson
13:10

Virtual Research: What it Is & What it’s Doing in the Real-World Setting

Ryan Saadi
13:30

Interview: Reflections on Medical Innovations in the time of COVID-19 Pandemic

13:50

Live Q/A Panel Discussion

EVIDENCE: Strategic Insight

PRICING & MARKET ACCESS: Value and Outcomes Based Contracting

RARE DISEASES: Patient Access, Value & Registries

HTA: Considerations & Latest Developments

THE FAR EAST & AUSTRALASIA: East Asia, Australia & New Zealand

14:30

Patient Access for Rare Disease – A HTA Perspective

Ruth Howells, Practice Leader, VP, Clarivate Analytics
15:00

Live Q/A Panel Discussion

15:00

Live Q/A Panel Discussion

15:00

Live Q/A Panel Discussion

15:00

Live Q/A Panel Discussion

15:00

Live Q/A Panel Discussion

EVIDENCE: Use of Evidence in Oncology and Commercial Strategy

PRICING & MARKET ACCESS: Access and Patient Centricity in Gene Therapies

RARE DISEASES: COVID-19 and Reimbursement Considerations

HTA: Considerations & Latest Developments

EMERGING MARKETS: Latin America

15:50

Adopting a patient centric approach to access for gene therapies

Nanxin (Nick) Li, Senior Director and Head, Health Economics and Outcomes Research (HEOR), uniQure
16:05

Live Q/A Panel Discussion

16:05

Live Q/A Panel Discussion

16:05

Live Q/A Panel Discussion

16:05

Live Q/A Panel Discussion

16:05

Live Q/A Panel Discussion

round tables
16:20

Roundtables

Roundtable 12: Virtual approaches for real-world research
Erwin De Cock

Erwin De Cock, Principal, Late Stage, Syneos Health

Roundtable 1: HTA: to collaborate or not? Secrets of partnering success
Akshay Kumar

Akshay Kumar, Partner, Partners4Access

Roundtable 2: Developments in pricing and patient access for speciality treatments
Jenny Ebert

Jenny Ebert, National Account Director, Ascendis Pharma

Roundtable 3: Oncology drug market: a high-growth, high-price therapeutic area
Elena Lungu

Elena Lungu, Manager Of Policy Development, Government of Canada (Canada)

Roundtable 4: The Modeling Impact of Policy Decisions on Pricing
Alan Crowther

Alan Crowther, General Manager, EVERSANA

Roundtable 5: Innovative and Value Based Agreements – more of the same, or solution for access?
Julien Patris

Julien Patris, Director Market Access & Policy – Europe / Canada / MEA (CEMEA), Alnylam

Roundtable 6: Pricing Competition from Launch to Loss of Exclusivity
Adam Plich

Adam Plich, Managing Director, Plich Advisory

Roundtable 7: Exploring access and pricing challenges for low to middle income countries
Marijn Verhoef

Marijn Verhoef, Engagement Manager, Access to Medicine Foundation

Roundtable 8: Access and pricing considerations for CAR-T development
Nuno Prego Ramos

Nuno Prego Ramos, Chief Executive Officer, Cellmabs

Roundtable 9: The use of real-world evidence to support outcomes-based pricing and reimbursement decisions: opportunities and challenges
Dimitrios Tsourougiannis

Dimitrios Tsourougiannis, Senior Hemar Manager, Janssen - Cilag Ltd

USA and International Reference Pricing – what will happen to confidential discounts in Europe?
Daniel Suhr

Daniel Suhr, Chief Executive Officer, Two Scenarios

EVIDENCE: Evidence Considerations for HTA & Post-launch

PRICING & MARKET ACCESS: Perspectives from across the world

RARE DISEASES: Patient Engagement

PAYER ENGAGEMENT & POLICY: Working with Payers & Policy Insight

EMERGING MARKETS : Middle East & Africa

17:05

Insights into the implementation of HTA recommendations: Understanding the evidence

Belen Corbacho, Health Economist, University of York
17:50

Live Q/A Panel Discussion

17:50

Live Q/A Panel Discussion

17:50

Live Q/A Panel Discussion

17:50

Live Q/A Panel Discussion

17:50

Live Q/A Panel Discussion

Chair’s Closing Remarks

Chair’s Closing Remarks

Chair’s Closing Remarks

Chair’s Closing Remarks

Chair’s Closing Remarks

last published: 19/Sep/20 18:55 GMT

Day 3 - Friday 25th September 2020

Morning Plenary

Panel discussion
10:20

Networking Break

round tables
11:00

Roundtables

Roundtable 2: Risk-sharing arrangements: Are they improving patient access to new medicines?
Catarina Lopes Pereira

Catarina Lopes Pereira, Global Market Access Manager, Medac

Roundtable 3: Exploring Biosimilars in the USA and Europe – latest developments
Sue Naeyaert

Sue Naeyaert, Advisor, Independent

Roundtable 4: How to establish a market access department from scratch?
Michael Muller

Michael Muller, Head Of Market Access, Western Europe, Sun Pharma

Roundtable 6: Exploring the international reference pricing landscape
Tanya Aiden

Tanya Aiden, Global Products Lead, BIOCAD

Roundtable 7: Market access, Pricing, Payer & HTA developments for the Nordic Region
Einar Andreassen

Einar Andreassen, Head of unit, HTA and Reimbursement, Norwegian Medicines Agency

Roundtable 8: Real world data and its utility in HTA decisions
Madhusudan Kabra

Madhusudan Kabra, Director, Evidence Generation, Otsuka Pharmaceutical

Roundtable 9: Exploring HTA requirements and novel payment methods for anti-biotics
Warren Cowell

Warren Cowell, Director Market Access UK, Shionogi Ltd

EVIDENCE: Real World Evidence

PRICING & MARKET ACCESS: Payment Methodologies, International Reference Pricing & Governance

RARE DISEASES: Innovation and Access

ADVANCED THERAPIES: Risk-sharing, Pricing and Investor Landscape for Advanced Therapies

12:35

The use of RWE in patient support programs

Priyal Sheth, Neuroscientist & VP of Business Development, Q1.6
12:35

Exploring repurposed products for rare diseases

Amer Omar, Senior Director, Lupin
12:50

Live Q/A Panel Discussion

12:50

Live Q/A Panel Discussion

12:50

Live Q/A Panel Discussion

12:50

Live Q/A Panel Discussion

round tables
13:05

Roundtables

Roundtable 1: Accelerating Access to treatments for Rare Diseases
Gina Ewy

Gina Ewy, Head Of Global Market Access, Hansa Biopharma

Roundtable 2: Exploring High Cost Novelty Medicine Access and HTA in South Africa
Niri Bhimsan

Niri Bhimsan, Head - Health Technology Assessment, Discovery Health

Roundtable 3: Opportunities & Challenges for Collection of RWD in Early Access Programs (EAPs)
Alastair Macdonald

Alastair Macdonald, Senior Vice President Of Real World And Late Phase, Syneos Health

Roundtable 5: Modelling the value of digital health innovations
Roundtable 6: The Modeling Impact of Policy Decisions on Pricing
Alan Crowther

Alan Crowther, General Manager, EVERSANA

Roundtable 7: What if you could listen to 1,000,000,000 authentic patient voices? Turning real-world conversations into evidence
Yannick Loonus

Yannick Loonus, Chief Sales Officer, Semalytix GmbH

Roundtable 8: Understanding Business Challenges of Shifting IV drugs to SC to Enable Self-delivery
Marie-Liesse Le Corfec

Marie-Liesse Le Corfec, Global Portfolio Marketing Head, Ps, B.D. Pharmaceuticals Systems

Roundtable 9: Achieving the best outcomes when negotiating managed entry agreements
Inneke Van De Vijver

Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, N.I.H.D.I.

EVIDENCE: Real World Evidence & Capability-Building

PRICING & MARKET ACCESS: Developments in Germany, EUnetHTA and South Africa

RARE DISEASES: Regulatory Landscape of Orphan Drugs

ADVANCED THERAPIES & PATIENT CENTRICITY: Considerations & Patient Centricity

14:10

A manufacturer’s move to patient-centricity

Scott Doyle, Senior Director, TA Head, Astellas
14:25

Develop robust RWE Analytics Capability to enable rapid evidence generation

Yonghua Jing, Director, Real World Evidence & Analytics, Health Economics & Outcomes Research, AbbVie
14:55

Live Q/A Panel Discussion

14:55

Live Q/A Panel Discussion

14:55

Live Q/A Panel Discussion

14:55

Live Q/A Panel Discussion

15:10

Networking Break

EVIDENCE: Real World Evidence

PRICING & MARKET ACCESS: Medical Devices & Patient Support Programs

RARE DISEASES: Collaborating with Pharma, HTAs & Payers to improve Access

ADVANCED THERAPIES: CAR-T & Reimbursement

16:00

The role of pharmacy in Patient Support Programs

Andrew Lane, Chair, National Pharmacy Association
16:30

Live Q/A Panel Discussion

16:30

Live Q/A Panel Discussion

16:30

Live Q/A Panel Discussion

16:30

Live Q/A Panel Discussion

Chair’s Closing Remarks

Chair’s Closing Remarks

Chair’s Closing Remarks

Chair’s Closing Remarks

last published: 19/Sep/20 18:55 GMT

Contact us

To sponsor or exhibit:
Edmond Rama
+44 (0)207 092 1052

edmond.rama@terrapinn.com

To speak:
Chris Shanks
+44 (0)207 092 1151

chris.shanks@terrapinn.com